JP Morgan Maintains Neutral on Conmed, Lowers Price Target to $40
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Robbie Marcus maintains Conmed (NYSE:CNMD) with a Neutral and lowers the price target from $43 to $40.
JP Morgan analyst Robbie Marcus maintains Conmed (NYSE:CNMD) with a Neutral and lowers the price target from $43 to $40.